A Single-center, Single-arm, Open-label Phase IIA Clinical Trial to Investigate Efficacy and Safety of Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria

The purpose of this research study is to see if a drug called ritlecitinib is safe and effective for treating chronic spontaneous urticaria (CSU). CSU is hives and itching lasting over six weeks. Ritlecitinib is approved by the Food and Drug Administration (FDA) to treat another condition, but it is not approved for treating CSU. Participation is expected to last 20 weeks and include 7 clinic visits. This study will involve physical examinations, blood tests, looking at and taking pictures of participant's skin and hives, optional skin biopsies, and hearing tests. Eligible participants for this study will take ritlecitinib for 12 weeks and complete a daily diary about their skin and hives. The main risks of being in this study are side effects from ritlecitinib. Less than 1 in 10 people taking ritlecitinib experience diarrhea, acne, hives, rash, inflammation of hair follicles, dizziness, and increased blood levels of creatine phosphokinase (a muscle protein). Participants could also experience a rare but serious side effect, such as shingles, unusual infection, cancer, or blood clot. Benefits of participating in this study include a potential improvement in participant's condition and quality of life. Participating in this study may also help researchers develop new ways of helping future patients.

Start Date31 Dec 2025

Sponsor / Collaborator

Icahn School of Medicine at Mount Sinai

NCT07226531

/ Active, not recruitingNot Applicable

RETROSPECTIVE COHORT STUDY TO ASSESS UTILIZATION AND EFFECTIVENESS OF RITLECITINIB IN A REAL-WORLD POPULATION WITH SEVERE ALOPECIA AREATA IN THE UNITED STATES

Alopecia areata (AA) is a chronic, relapsing T-cell mediated autoimmune disease characterized by nonscarring, typically patchy hair loss that affects people of all ages, races, and genders. In the United States (US), AA has an estimated point prevalence of 1.14% (Beningo et al., 2020). The three most common subtypes of AA are defined by the affected area:
* Patchy alopecia (PA), as seen in 90% of clinical diagnoses: hair loss occurring in one or more patches (ranging from coin-sized to large patches and even full scalp involvement) on the scalp or other parts of the body;
* Alopecia totalis (AT): loss of all or nearly all scalp hair;
* Alopecia universalis (AU): loss of all or nearly all scalp, face, and body hair Traditionally, a range of medications, including corticosteroids, immunotherapy, and minoxidil, are used to treat AA. However, few of these mainstay therapies are supported by robust clinical evidence, limiting the development of widely accepted clinical practice guidelines (Asfour et al., 2023). As a result of suboptimal effectiveness of traditional therapies, patients with AA, particularly those with extensive hair loss, have a persistent unmet medical need. Furthermore, the potential effects of AA on other subgroups, including patients with skin of color, remain undefined. As these subgroups have been historically underrepresented in clinical trials, an additional unmet medical need and evidence gap exists for these patients.
Recent clinical studies have demonstrated efficacy of novel treatments for AA, including ritlecitinib, a JAK3/TEC family kinase inhibitor developed and marketed by Pfizer (King et al., 2023). Ritlecitinib was approved by the US Food and Drug Administration (FDA) in June 2023 for the treatment of severe AA in adults and adolescents aged 12 years or older. Extensive information from clinical trials exists on the safety and efficacy of ritlecitinib, which, along with JAK inhibitors such as baricitinib and deuruxolitinib that are FDA approved for severe alopecia areas in adults 18 and over, have presented needed new therapeutic options for these patients. However, little is known about the clinical effectiveness of ritlecitinib in real-world clinical practice.
The objective of the current study is to evaluate patient characteristics, treatment patterns and related clinical outcomes of patients who initiated ritlecitinib to treat severe AA.

Start Date22 Dec 2025

Sponsor / Collaborator

Pfizer Inc.

NCT07228390

/ RecruitingPhase 2

A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 16-WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF RITLECITINIB (PF-06651600) IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA

The purpose of this study is to learn about the safety and effects of the study medicine (called Ritlecitinib) for the possible treatment of hidradenitis suppurativa (HS). HS is a disease causing long lasting painful red skin lumps.
This study is seeking participants who:
* have moderate or severe HS
* have previously received antibiotics for HS that did not help, or could not tolerate antibiotics Participants will be randomly (like a flip of coin) assigned to receive either the study medicine or a placebo (a pill that looks like the study medicine but does not contain any medicine). The study medicine or placebo will be taken by mouth once daily at home. For the first part of the study, participants will receive a loading (starting) dose. For the next part of the study, participants will receive a maintenance (ongoing) dose.
Participants will take part in the study for about 24 weeks (about 6 months). There will be about 10 study clinic visits: a screening visit, Day 1, and then every 1, 2, or 4 weeks until week 16. At each visit, participants will report on their health and have tests such as physical exams, blood and urine tests, vital signs, chest X-rays, ECGs, hearing tests, and questionnaires. Participants will record when they take the study medicine and their HS symptoms every day in an eDiary on a mobile phone.
The experiences of participants receiving the study medicine will be compared to those receiving placebo to help see if the study medicine is safe and effective.

Start Date13 Nov 2025

Sponsor / Collaborator

Pfizer Inc.

100 Clinical Results associated with Ritlecitinib Tosilate

100 Translational Medicine associated with Ritlecitinib Tosilate

100 Patents (Medical) associated with Ritlecitinib Tosilate

233

Literatures (Medical) associated with Ritlecitinib Tosilate

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Patient preferences for treatment characteristics of Janus kinase inhibitors for alopecia areata: a discrete choice experiment

Article

Author: Barghout, Victoria ; Mostaghimi, Arash ; Mesinkovska, Natasha ; Deering, Kathleen L. ; Harshaw, Qing ; Ferro, Thomas J.

BACKGROUND:

Janus kinase inhibitors (JAKis) can improve hair regrowth in alopecia areata (AA).

OBJECTIVE:

This study examined which treatment attributes patients value most when evaluating hypothetical JAKi-based therapies.

METHODS:

A discrete choice experiment was conducted among adults with ≥50% hair loss, recruited through the National Alopecia Areata Foundation (February-March 2024). Participants completed 10 binary choices comparing three hypothetical JAKi attributes: proportion with scalp hair regrowth, time to initial hair regrowth, and dosing frequency; safety attributes were held constant across profiles because the safety profiles were similar among JAKis approved for AA. Relative importance (RI) was calculated using preference weights. Additionally, participants ranked three blinded treatment profiles developed from phase 2b-3 data: drug profile A (baricitinib 4 mg), drug profile B (ritlecitinib 50 mg), and drug profile C (deuruxolitinib 8 mg).

RESULTS:

Among 302 patients (85% women, 81% White, mean age 43.2 years), the most valued attribute was scalp regrowth (RI = 60.0%), followed by time to initial regrowth (28.2%) and dosing frequency (11.7%). Drug profile C was most preferred (83%), and drug profile B was least preferred (85%).

CONCLUSION:

When considering efficacy only, patients prioritize higher efficacy and faster time to hair regrowth above dosing convenience in JAKi treatment preferences for AA.

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study

Article

Author: Lei, Ziyi ; Cen, Junjie ; Zhan, Jinshan ; Xu, Yantao ; Wan, Miaojian ; Tang, Xin

METHODS:

Reports associated with JAK inhibitors in AA (2015-2025) were retrieved from the FDA Adverse Event Reporting System (FAERS). Disproportionality analyses utilized within-class and external non-JAK comparisons. Additionally, time-to-onset (TTO), serious adverse event (SAE) profiles, and sensitivity analyses were assessed.

RESULTS:

Among 1,905 identified reports (baricitinib [n = 881], ritlecitinib [n = 515], tofacitinib [n = 489], ruxolitinib [n = 20]), safety signals varied across agents. Tofacitinib showed signals involving neuropsychiatric and autoimmune events; baricitinib was associated with thrombocytosis, deep vein thrombosis, and breast cancer; ruxolitinib with pyrexia and elevated blood cholesterol; and ritlecitinib with gastrointestinal events and creatine phosphokinase elevation. TTO patterns were also heterogeneous, with earlier onset for tofacitinib and ruxolitinib, clustering within the first month for ritlecitinib, and a relatively delayed onset for baricitinib. Across the class, serious outcomes were most commonly related to infections, although the distribution of clinical outcomes differed by agent.

CONCLUSIONS:

JAK inhibitors used in AA demonstrated heterogeneous post-marketing safety patterns not fully captured by class-level warnings. These findings support agent-specific surveillance and individualized risk assessment in clinical practice.

01 Aug 2026·CURRENT OPINION IN PHARMACOLOGY

Alopecia areata: Mechanisms, targeted therapies, and translational challenges

Review

Author: Kumar, Pawan ; Kumar, Virender ; Sahoo, Saurabh

Alopecia areata (AA) is an immune-mediated disorder characterized by non-scarring hair loss and substantial psychosocial burden. Although recent advances have clarified key pathogenic mechanisms and expanded therapeutic options, important uncertainties persist regarding disease heterogeneity, treatment durability, and long-term safety. Central to AA pathogenesis is the collapse of hair follicle immune privilege, driven primarily by cytotoxic CD8⁺ NKG2D⁺ T-cells and sustained by interferon-γ-dependent Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling. However, emerging evidence indicates immunological variability across patient subsets, including inconsistent contributions from T helper cell pathways and regulatory immune dysfunction. The clinical approval of JAK inhibitors-baricitinib, ritlecitinib, and deuruxolitinib-represents a major therapeutic milestone, validating targeted immune modulation as an effective strategy for moderate-to-severe AA. Nevertheless, relapse following treatment discontinuation, interindividual variability in response, and unresolved long-term safety considerations highlight the limitations of current approaches. In parallel, regenerative therapies, microbiome-based interventions, gene-targeted strategies, and device-assisted technologies are under investigation, yet most face substantial translational, regulatory, and scalability challenges. This review critically synthesizes current evidence on AA pathogenesis and therapy, with particular emphasis on unresolved controversies, translational barriers, and clinical implications. By integrating mechanistic insights with emerging clinical data, the article highlights priorities for future research, including biomarker development, precision medicine approaches, and strategies aimed at achieving durable disease control rather than transient immune suppression.

News (Medical) associated with Ritlecitinib Tosilate

20 Apr 2026

·firstwordpharma.com

Nektar says rezpeg shows more hair regrowth in alopecia over longer period

New Phase IIb results suggest Nektar Therapeutics' rezpegaldesleukin (rezpeg) may deliver greater hair regrowth in severe alopecia areata over time. Company shares jumped over 24% on the news Monday.The readout comes from a 16-week blinded extension of the REZOLVE-AA trial, taking total treatment duration to one year. It builds on 36-week data from the study first reported in December, when Nektar said results had "narrowly missed" significance on the primary endpoint of mean reduction in Severity of Alopecia Tool (SALT) score, but cleared the bar once four patients with major "eligibility violations" were dropped from the analysis.REZOLVE-AA includes 92 patients with severe-to-very-severe alopecia areata who have not previously been treated with a JAK inhibitor or other biologic.Participants were initially randomised to receive one of two rezpeg doses or placebo, given as twice-monthly subcutaneous injections, over 36 weeks. The drug targets the IL-2 receptor complex and is designed to modulate immune activity by stimulating proliferation of regulatory T cells, which act as a brake on autoimmune responses.Patients who experienced hair regrowth at the 36-week mark, but still had a SALT score of >20, were allowed to continue on rezpeg at the same induction dose for another 16 weeks.Response growsNektar said that over that time, continued treatment produced more responders: 29% of patients at the low dose and 31% on the high dose reached a SALT score of 20 or less – meaning they had hair now covering at least 80% of their scalp – while there were no such gains with placebo.By week 52, the share of patients in the overall population reaching a SALT score of ≤20 had climbed to 25.8% in the low-dose group and 27.6% in the high-dose arm, up from 14.8% and 15.6%, respectively, at the earlier 36-week mark.Additionally, 30.2% of patients on the low dose and 35% on the high dose achieved a SALT score ≤30, which indicates at least 70% scalp hair coverage. Nektar said both figures represent gains over the week 36 results of 21.9% and 29%, respectively, while the rate for placebo was unchanged at 8.4%.Safety findings remained in line with prior studies, according to Nektar, with most treatment-emergent adverse events classified as mild-to-moderate and no treatment discontinuations during the extension phase. Nearly all participants completed the additional 16 weeks of dosing, and injection-site reactions that resolved on its own were the most commonly reported side effect.'Cautiously optministic'The company has said the results support advancing rezpeg into late-stage testing this year in alopecia areata, an indication that currently may involve treatment with daily oral JAK inhibitors such as Eli Lilly's Olumiant (baricitinib) and Pfizer's Litfulo (ritlecitinib) which carry boxed warnings about serious infections, malignancy, major adverse cardiovascular events and thrombosis."We are cautiously optimistic on [rezpeg's] prospects in alopecia," said Wedbush analyst Martin Fan, though he remains skeptical on its use in atopic dermatitis, where the drug nevertheless has also shown signs of deepening effect with longer use (see – Spotlight On: Never mind Dupixent – Nektar’s rezpeg puts anti-OX40s on notice in atopic dermatitis).Rezpeg is also in a Phase II study for type 1 diabetes.

Clinical ResultPhase 2

24 Oct 2025

·www.pharmaceutical-technology.com

Lilly and Incyte to seek approval of alopecia JAK inhibitor in children

If approved, Lilly and Incyte’s drug could be the first treatment available for alopecia areata patients aged under 12 years. Image credit: Tada Images / Shutterstock.com. Eli Lilly and Incyte’s oral JAK inhibitor has shown benefit in hair regrowth in paediatric patients with severe alopecia areata. In the Phase III BRAVE-AA-PEDS trial (NCT05723198) 54.1% and 31% of patients receiving Olumiant (baricitinib) 4mg and 2mg, respectively, achieved successful hair regrowth, defined as 80% or more scalp hair coverage, after 52 weeks. In addition, 41.2% of patients in the high dose cohort and 26.2% in the low dose cohort achieved near-complete scalp hair regrowth, defined as 90% or more scalp hair coverage. Among those with severe disease, 71% in the high-dose group and 58.6% in the low-dose group achieved successful hair regrowth. In regard to eyebrow regrowth, improvements in hair coverage were seen in 64.8% of patients receiving Olumiant 4mg and 27.8% of patients receiving Olumiant 2mg. Meanwhile, 63.3% and 34% taking the 4mg and 2mg tablet, respectively, achieved eyelash regrowth. Based on the Phase III trial, Lilly intends to submit the adolescent data to global regulators for a label update for Olumiant to be used in paediatric patients. If the label is extended to the trial population, it would be a notable development for paediatric patients, as there is just one approved treatment – Pfizer’s Litfulo (ritlecitinib) – for adolescents aged over 12 with severe alopecia areata. Lilly and Incyte’s drug would provide an option for patients between six and 11 years for which there are currently no treatments. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence National Alopecia Areata Foundation (NAAF) president Nicole Friedland said: “For nearly half of the people with severe alopecia areata, the disease starts before adulthood and can progress quickly, significantly impacting patients’ lives. Given the profound burden of this disease, new treatment options are needed for children and adolescents, populations that have been underrepresented for far too long.” The trial enrolled 595 children aged between six to under 18 years with severe alopecia areata, as measured by a Severity of Alopecia Tool (SALT) score of ≥50. The safety profile remained consistent within the paediatric population as that reported in adults. Full data will be presented at the 2025 Fall Clinical Dermatology (FCD) Conference, taking place in Las Vegas between 23 and 26 October. Olumiant is a once-daily, oral JAK inhibitor discovered by Incyte and licensed to Lilly in December 2009. The therapy was approved by the US Food and Drug Administration in 2022 for adult patients with severe alopecia areata . According to GlobalData’s annual sales and consensus forecast, Olumiant’s sales peaked at $1.15bn in 2021; however, sales started to increase again in 2023, with a 2031 sales forecast of $1.09bn. GlobalData is the parent company of Clinical Trials Arena. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

Clinical ResultPhase 3Drug Approval

15 Oct 2025

·endpoints.news

Hair loss biotech Pelage collects $120M for Phase 3 trials

In the span of three weeks, a seven-employee biotech focused on hair loss raised $120 million for Phase 3 trials that will begin next year. Los Angeles-based Pelage Pharmaceuticals announced the Series B on Wednesday morning. Existing investor GV co-led the round with new supporter ARCH Venture Partners, one of the most prolific venture capital firms in the life sciences industry. Backing from the two well-known firms will boost the profile of the small startup, which aims to take on one of the most difficult fields of drug development. GV supported Pelage’s Series A, which initially came in at nearly $17 million in February 2024 and was expanded six months later to include another $14 million. Born out of UCLA basic science research, Pelage aims to activate dormant hair follicle stem cells using an experimental drug called PP405. “People understand the unmet need in hair loss. As we see more and more hair loss with medications like GLP-1s, more awareness of hair loss during perimenopause, menopause, other conditions, that’s going to continue to grow,” Pelage chief medical officer Christina Weng said in an interview. Hello, Brian Miles! You’re an essential part of the biopharma world. Share your voice on this subscriber Pulse Survey to help shape our understanding of the industry. Results will be anonymous. Hello, Brian Miles! You’re an essential part of the biopharma world. Share your voice on this subscriber Pulse Survey to help shape our understanding of the industry. Results will be anonymous. Hello, Brian Miles! You’re an essential part of the biopharma world. Share your voice on this subscriber Pulse Survey to help shape our understanding of the industry. Results will be anonymous. Hello, Brian Miles! You’re an essential part of the biopharma world. Share your voice on this subscriber Pulse Survey to help shape our understanding of the industry. Results will be anonymous. Hello, Brian Miles! You’re an essential part of the biopharma world. Share your voice on this subscriber Pulse Survey to help shape our understanding of the industry. Results will be anonymous. Hello, Brian Miles! You’re an essential part of the biopharma world. Share your voice on this subscriber Pulse Survey to help shape our understanding of the industry. Results will be anonymous. Hello, Brian Miles! You’re an essential part of the biopharma world. Share your voice on this subscriber Pulse Survey to help shape our understanding of the industry. Results will be anonymous. Hello, Brian Miles. You’re an essential part of the biopharma world. Share your voice on this subscriber Pulse Survey to help shape our understanding of the industry. Results will be anonymous. “This is a case where we really understand the biological mechanisms of its action. We understand the science. It’s really a drug designed for the 21st century,” she said. The topical treatment PP405 has drummed up attention in recent months as it goes through the clinical trial process, with TIME naming it one of the best inventions of 2025. There’s been little innovation on the hair loss front in recent decades. Now-generic drugs minoxidil and finasteride have long comprised the bulk of the market. Neutraceuticals, low-level light therapy helmets and hair transplantation have also received attention. There are approved treatments for some forms of hair loss caused by autoimmune diseases, including Pfizer’s Litfulo for alopecia areata . Pelage’s small molecule has been through Phase 2a testing in the US. In June, the regenerative medicines company said the once-daily topical helped improve hair density versus placebo. The trial included 78 men and women with androgenetic alopecia. A “diverse range of skin phototypes and hair textures” was included in the randomized trial, Pelage said. Now, equipped with a Series B, Pelage will be able to get all the way through two Phase 3 trials in androgenetic alopecia, which will begin next year, CEO Daniel Gil said in the joint interview with Weng. Gil declined to provide details on the Phase 3 timeline or trial designs. It will likely be at least a couple years before PP405 could make it onto the market since the company will need to collect at least 12 months of safety data on some of the patients as required by the FDA. “Definitely we can understand the impatience on one side, but also it is important to remind folks that running rigorous clinical trials is a process,” Weng said. The biotech is building out its operations to be able to commercialize the topical as an independent company, though an IPO, partnership or acquisition could come along the way, Gil said. AbbVie had the option to buy the biotech, but passed on the opportunity a few years ago, Endpoints previously reported . “A company that has a broad reach in terms of various types of channels, various types of physician practices would be an ideal partner,” Gil said. Dermatologists wouldn’t be the only type of physicians prescribing a medication like PP405, he said. Existing backers also took part in the Series B, including Main Street Advisors, Visionary Ventures and YK Bioventures. Pelage on Wednesday also named GV executive venture partner Cathy Friedman as the chair of its board. ARCH venture partner Rich Heyman is also joining the board. Heyman’s board credentials include ORIC Pharmaceuticals, Enliven Therapeutics and Architect Therapeutics.

Phase 2Phase 3Executive Change

100 Deals associated with Ritlecitinib Tosilate

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB14924

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Alopecia Areata	United States	Pfizer Inc.	23 Jun 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Nonsegmental vitiligo	Phase 3	United States	Pfizer Inc.	01 Dec 2022
Nonsegmental vitiligo	Phase 3	China	Pfizer Inc.	01 Dec 2022
Nonsegmental vitiligo	Phase 3	Japan	Pfizer Inc.	01 Dec 2022
Nonsegmental vitiligo	Phase 3	Australia	Pfizer Inc.	01 Dec 2022
Nonsegmental vitiligo	Phase 3	Bulgaria	Pfizer Inc.	01 Dec 2022
Nonsegmental vitiligo	Phase 3	Canada	Pfizer Inc.	01 Dec 2022
Nonsegmental vitiligo	Phase 3	Germany	Pfizer Inc.	01 Dec 2022
Nonsegmental vitiligo	Phase 3	India	Pfizer Inc.	01 Dec 2022
Nonsegmental vitiligo	Phase 3	Italy	Pfizer Inc.	01 Dec 2022
Nonsegmental vitiligo	Phase 3	Mexico	Pfizer Inc.	01 Dec 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05583526 \| NCT06163326 \| NCT06072183 (Tranquillo, Pubmed \| Dermatol Ther (Heidelb))	Phase 3	Nonsegmental vitiligo	1,990	Ritlecitinib 100 mg	wnkxgsflzt(gcmeifyivf) = euvwtalnwp uxzwwxrdtl (sbkogpfntx ) View more	Positive	22 May 2026
	Phase 3	Nonsegmental vitiligo	1,990	Placebo	rmnmcpssdg(xmcpckmvml) = zngumbjyka pxproglvxl (xdbxoajvtp )	Positive	22 May 2026
NCT03732807 (ALLEGRO-2b/3, AAD2026)	Phase 2	Alopecia Areata	27	Ritlecitinib 50 mg	agugyejpkp(cdkfubwscb) = xbwtrjygau smgeicypuh (xtrhofdeud ) View more	Positive	27 Mar 2026
AAD2026	Not Applicable	Alopecia Areata	32	Ritlecitinib 50mg	vqcmlnddlz(ztgjskfnfo) = jlvntjfbih srrayrsyqm (lfraodcawl ) View more	Positive	27 Mar 2026
NCT03732807 (ALLEGRO-2b/3, AAD2026)	Phase 2/3	Alopecia Areata	300	Ritlecitinib 50 mg	berrjxystp(lrhzamsnyy) = vqsxshxdbp rfcjlaueaq (bxqotmxzwp ) View more	Positive	27 Mar 2026
AAD2026	Not Applicable	Alopecia Areata	129	Tofacitinib	jbooqfebtp(ciqwmdicls) = bzjkhtwhvt rrwsaksfjv (jznfiwmvry ) View more	Negative	27 Mar 2026
AAD2026	Not Applicable	Alopecia Areata	129	Baricitinib	dmyqxdfhkk(ybtfbvknxs) = axmemmzhje xhnswwsfbm (uzixbgijtw )	Negative	27 Mar 2026
AAD2026	Not Applicable	Alopecia Universalis	329	Tofacitinib	vzzlorlfyg(yoeheezwfh) = Tofacitinib was associated with shingles, acneiform eruptions, infections, gastrointestinal symptoms, weight gain, and one case of multiple sclerosis. Ruxolitinib caused mild cytopenias and gastrointestinal issues; upadacitinib led to hair depigmentation; filgotinib caused acneiform eruptions. Safety data for ritlecitinib, abrocitinib, and deuruxolitinib were limited. zgyizzhbma (kpzjnghjnm )	Positive	27 Mar 2026
NCT03732807 (ALLEGRO, Pubmed \| Value Health)	Phase 2/3	Alopecia Areata	201	Ritlecitinib 50 mg once daily	eqvaektnun(xbrqmfkuib) = dnwrgdmcij tmblaeuiea (xjmbinvxiy ) View more	Positive	01 Feb 2026
NCT04006457 (ALLEGRO \| ALLEGRO-LT, CTgov)	Phase 3	Alopecia Areata	1,057	Ritlecitinib (Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants))	nkoqzwrkmg = hdlwtagbri quvlnvpbau (jybxuhcyke, qsxzmfgyqk - sgwvjblgmz) View more	-	14 Aug 2025
NCT04006457 (ALLEGRO \| ALLEGRO-LT, CTgov)	Phase 3	Alopecia Areata	1,057	Ritlecitinib (Main Study: Ritlecitinib 50 mg QD (Roll-over Participants))	nkoqzwrkmg = ouyjfnhnqo quvlnvpbau (jybxuhcyke, npqwbfhlsn - lmoorkdilp) View more	-	14 Aug 2025
NCT03732807 \| NCT04006457 (ALLEGRO, Pubmed \| J Eur Acad Dermatol Venereol)	Phase 2/3	Alopecia Areata	191	Ritlecitinib 50 mg	jvuqglkeql(delfqwypqg) = kkbkefujlm oganmkpmnu (lsefjpcues ) View more	Positive	01 Jun 2025
NCT04006457 (ALLEGRO-LT, Pubmed \| J Eur Acad Dermatol Venereol)	Phase 3	Alopecia Areata	449	Ritlecitinib 200mg loading dose followed by 50mg daily	uuitmvrmtz(zrhowiyupt) = occurred in six patients kxrbvegyaf (iezuipybhb ) View more	Positive	01 Jun 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis